Results 51 to 60 of about 5,752,243 (395)

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]

, 2012
Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
A Barbarulo, A Chaidos, A Karadimitris, A Rahemtulla, AJ Bardwell, C Bubici, C-H Yoon, CG Pham, CR Geest, D Chauhan, D O Haskard, E Spanoudakis, EF Wagner, F Bost, F Zazzeroni, F Zhan, F Zhan, G Franzoso, H Ke, H Ke, J Cui, J Cui, J Ford, J Liu, K Kim, K Naresh, K Pruitt, K Sabapathy, KC Anderson, KN Naresh, L Aravind, L Hui, LC Platanias, M Anbalagan, M Blonska, M Gururajan, M Hallek, M Raman, M Wiznerowicz, MA Bogoyevitch, MA Bogoyevitch, MS Raab, N Chen, NJ Kennedy, NN Gangopadhyay, RT Nitta, S Goenka, S Goenka, S Papa, S Papa, SH Cho, SH Cho, SU Ahmed, SV Rajkumar, T Hideshima, T Hideshima, T Hideshima, T Kajiguchi, T Yanagawa, TE Witzig, V Brune, V Iansante, V Schreiber, YM Yang   +63 more
core   +2 more sources

Myeloma multiplex with pulmonary dissemination [PDF]

, 2014
Introduction. Multiple myeloma is a hemathological malignancy characterized by the clonal proliferation of plasma cells in the bone the marrow. Extramedullary dissemination of multiple myeloma is uncommon.
Maksić Đoko, Mijušković Mirjana, Obrenčević Katarina, Petrović Marijana, Petrović Milica, Pilčević Dejan, Tadić-Pilčević Jelena, Terzić Brankica, Čukić Zoran, Škuletić Vesna   +9 more
core   +1 more source

Talquetamab in multiple myeloma

Haematologica, 2023
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting.
Lawrence Liu, Amrita Krishnan
doaj   +1 more source

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Journal of Clinical Oncology, 2015
PURPOSE The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase ...
A. Palumbo, H. Avet-Loiseau, S. Oliva, H. Lokhorst, H. Goldschmidt, L. Rosiñol, P. Richardson, S. Caltagirone, J. Lahuerta, T. Facon, S. Bringhen, F. Gay, M. Attal, R. Passera, A. Spencer, M. Offidani, Shaji K. Kumar, P. Musto, S. Lonial, M. Petrucci, R. Orlowski, E. Zamagni, G. Morgan, M. Dimopoulos, B. Durie, K. Anderson, P. Sonneveld, J. S. San Miguel, M. Cavo, S. Rajkumar, P. Moreau   +30 more
semanticscholar   +1 more source

MULTIPLE MYELOMA [PDF]

JAMA: The Journal of the American Medical Association, 1922
n ...
openaire   +2 more sources

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Journal of Clinical Oncology, 2020
PURPOSE Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma.
S. Lonial, S. Jacobus, R. Fonseca, M. Weiss, Shaji K. Kumar, R. Orlowski, J. Kaufman, Abdulraheem M. Yacoub, F. Buadi, T. O'brien, J. Matous, Daniel M. Anderson, Robert V. Emmons, A. Mahindra, Lynne I. Wagner, M. Dhodapkar, S. Rajkumar   +16 more
semanticscholar   +1 more source

Widespread intronic polyadenylation diversifies immune cell transcriptomes

Nature Communications, 2018
Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh, Shih-Han Lee, Adam S. Sperling, Mehmet K. Samur, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie   +8 more
doaj   +1 more source

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Cancers, 2020
Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies.
Vanessa Pinto, Rui Bergantim, H. Caires, H. Seca, J. Guimarães, M. Vasconcelos   +5 more
semanticscholar   +1 more source

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics

Blood Cancer Journal, 2023
Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed.
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia   +14 more
doaj   +1 more source

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

Frontiers in Oncology, 2021
Multiple myeloma (MM) is an incurable malignancy of plasma cells that grow within a permissive bone marrow microenvironment (BMM). The bone marrow milieu supports the malignant transformation both by promoting uncontrolled proliferation and resistance to
Leona Yamamoto, Nicola Amodio, Annamaria Gulla, Kenneth Carl Anderson   +3 more
doaj   +1 more source